Skip to main content
PLOS One logoLink to PLOS One
. 2022 May 18;17(5):e0268563. doi: 10.1371/journal.pone.0268563

Intracellular dynamics of the Sigma-1 receptor observed with super-resolution imaging microscopy

Sergei Kopanchuk 1, Edijs Vavers 2,3,*, Santa Veiksina 1, Kadri Ligi 1, Liga Zvejniece 2, Maija Dambrova 2,3, Ago Rinken 1,*
Editor: Jean-Pierre Mothet4
PMCID: PMC9116656  PMID: 35584184

Abstract

Sigma-1 receptor (Sig1R) is an endoplasmic reticulum (ER)-related membrane protein, that forms heteromers with other cellular proteins. As the mechanism of action of this chaperone protein remains unclear, the aim of the present study was to detect and analyze the intracellular dynamics of Sig1R in live cells using super-resolution imaging microscopy. For that, the Sig1R-yellow fluorescent protein conjugate (Sig1R-YFP) together with fluorescent markers of cell organelles were transfected into human ovarian adenocarcinoma (SK-OV-3) cells with BacMam technology. Sig1R-YFP was found to be located mainly in the nuclear envelope and in both tubular and vesicular structures of the ER but was not detected in the plasma membrane, even after activation of Sig1R with agonists. The super-resolution radial fluctuations approach (SRRF) performed with a highly inclined and laminated optical sheet (HILO) fluorescence microscope indicated substantial overlap of Sig1R-YFP spots with KDEL-mRFP, slight overlap with pmKate2-mito and no overlap with the markers of endosomes, peroxisomes, lysosomes, or caveolae. Activation of Sig1R with (+)-pentazocine caused a time-dependent decrease in the overlap between Sig1R-YFP and KDEL-mRFP, indicating that the activation of Sig1R decreases its colocalization with the marker of vesicular ER and does not cause comprehensive translocations of Sig1R in cells.

Introduction

The non-opioid sigma-1 receptor (Sig1R) has been described as an intracellular protein modulator, a chaperone protein that localizes in the endoplasmic reticulum (ER) [1]. It was thought that, upon stimulation by agonists or cell stress, Sig1R can translocate from the ER to the plasma membrane, where it interacts with and affects the function of other receptors, ion channels, and kinases [2]. For example, atomic force microscopy imaging confirmed the direct binding of Sig1R to the hERG potassium channel within the plane of the plasma membrane [3]. However, APEX2-enhanced electron microscopy revealed that Sig1R localizes in the ER and nucleoplasmic reticulum but not in the plasma membrane [4]. To date, it is not fully understood how ER-resident Sig1R can translocate within the ER and interact with other proteins, especially those located on the plasma membrane. As described previously, it seems more likely that the interactions between Sig1R and plasma membrane-resident proteins could only be formed at the proximity between the ER and the plasma membrane [2]. The mechanism of action and intracellular dynamics of Sig1R remain unclear, hindering the understanding of the functional nature of Sig1R.

Several selective fluorescent Sig1R ligands have been developed for imaging in cells using microscopy techniques [5]. However, only a few studies have demonstrated the dynamics of Sig1R in live cells using a fluorescence imaging approach. For example, in live neuroblastoma-glioma NG108-15 cells, Sig1R dynamics have been demonstrated using Time-Lapse Fluorescence microscopy [6]. The movement of activated yellow fluorescent protein (YFP)-tagged Sig1R from lipid-enriched globules to tubular elements on the ER has been demonstrated with real-time monitoring by confocal microscopy [7]. The subcellular and functional dynamics of Sig1R have also been studied using live-cell imaging of fluorescently tagged wild-type and mutant Sig1R-YFP in mouse embryonic fibroblasts and Chinese hamster ovary cells [8]. Even so, the detection of Sig1R in cells is still technically challenging due to the lack of specific high-affinity Sig1R antibodies and fluorescently labeled probes [2]. Confocal microscopy with FRAP assays have provided the first hints about the agonist-dependent increased mobility of Sig1R-YFP [8]. However, the resolution limit of the assays does not allow us to obtain sufficiently detailed information about the protein-protein interactions or precise cellular mobility of Sig1R.

In recent years, several new methods in fluorescence microscopy have been developed, enabling the achievement of higher resolution than the diffraction limit of light. Most of these methods require sophisticated hardware and special experimental design, such as STED, SIM, and PALM [9], but there are also several algorithm-based methods, such as FAstLocalization algorithm based on a CONtinuous-space formulation (FALCON) [10] and the super-resolution radial fluctuations (SRRF) [11]. These later methods enable super-resolution with temporal resolution in the low-seconds range [10]. Recently, to achieve super-resolution level, protein retention expansion microscopy (pro-ExM) was applied to demonstrate Sig1R expression in mitochondria-associated membranes (MAMs) [12].

In the present study, we used SRRF to detect and analyze the intracellular dynamics of Sig1R in live cells after pharmacological activation with selective ligands and found time-dependent changes in the colocalization of Sig1R with KDEL-mRFP, a marker of the vesicular ER.

Materials and methods

Plasmid constructions and generation of BacMam viruses

BacMam technology was used for cotransfection of human ovarian adenocarcinoma (SK-OV-3) cells with Sig1R-YFP conjugate and fluorescent markers of the ER and mitochondria as we have described earlier [13]. The expression vector for pcDNA3.1(+)-Sig1R-YFP [14] was kindly provided by Prof. P. McCormick from the University of London. The Sig1R-YFP construct, under the control of the cytomegalovirus (CMV) promoter, was cloned into the pFastBac1 vector (Invitrogen Life Technologies) using restriction enzymes (Fermentas, Vilnius, Lithuania) RruI and NotI for pcDNA3.1(+) and NotI and Eco105I for pFastBac1, respectively. To ensure low promoter interference during BacMam virus amplification, the polyhedrin promoter was removed from the pFastBac1 vector.

The construct of a fluorescent marker targeting the ER lumen, KDEL-mRFP [15], was kindly provided by Prof. Erik L. Snapp from the Albert Einstein College of Medicine. The mitochondrial marker pmKate2-mito was obtained from Evrogen JSC (cat.# FP187).

The previous scheme was used for cloning of these markers into the pFastBac1 vector and production of recombinant bacmid DNA, with the exception that PciI and NotI restriction enzymes were used for pmRFP-N1 and for pmKate2-mito, while PciI and Eco105I were used for pFastBac1.

All generated pFastBac1 constructs were verified by sequencing. Then, the Bac-to-Bac baculovirus system was used according to the manufacturer’s recommendations (Thermo Fisher Scientific, Invitrogen) to transform the obtained pFastBac constructs into DH10Bac competent cells for the production of recombinant bacmid DNAs. All obtained bacmid DNAs were PCR-verified and then transfected into Sf9 insect cells by using FuGENE 6 Transfection Reagent (Promega). BacMam viruses were harvested and further amplified to high-titer viral stocks (in the range of 108 virus particles per milliliter). Virus titers were determined by image-based cell-size estimation (ICSE) assay [16]. For long-term storage, viral stock aliquots were stored at -90°C; working viral stocks were stored at 4°C.

SK-OV-3 cell culturing and transfection

SK-OV-3 cells (human ovarian adenocarcinoma, ATCC HTB-77) were maintained as a monolayer culture on cell culture treated 6-well multidishes (Thermo Scientific™, Bio-Lite) in McCoy’s 5A Medium supplemented with 10% FBS, 2 mM L-glutamine, 100 U/ml penicillin, and 100 μg/ml streptomycin at 37°C in humidified 5% CO2 cell incubator.

For cell membrane preparations, SK-OV-3 cells were grown on 10 cm2 treated Petri dishes (Thermo Scientific™, Nunc™). Recombinant BacMam baculoviruses of Sig1R-YFP were added to the cells (approximately 70% confluence) at an MOI of 3 and incubated for ≈24 h (medium was supplemented with 10 mM sodium butyrate (final concentration). An MOI = 3 was found to be optimal to achieve transfection of the majority of cells (Fig 1B) but not too high to initiate the generation of protein aggregates into cytoplasmic inclusion bodies.

Fig 1. Ligand binding properties of Sig1R-YFP in SK-OV-3 cells.

Fig 1

(A) Overview of binding experiments performed (created with Biorender.com). (B) SK-OV-3 cells were transfected with recombinant Bac-Mam baculoviruses expressing Sig1R-YFP (MOI = 3). The expression of the receptors was visualized with a 4× objective in brightfield (gray) and epifluorescence of YFP (green) channels. Scale bar = 100 μm. (C) Comparison of the binding of [3H](+)-pentazocine to membranes of SK-OV-3 and SK-OV-3-Sig1R-YFP cells. The data are presented as the means ± SEM (n = 6). NSB–nonspecific binding determined in the presence of 10 μM haloperidol. (D) Specific binding of [3H](+)-pentazocine to membranes of SK-OV-3-Sig1R-YFP cells. The specific binding (Bound) was defined as the difference between total and nonspecific binding, measured in the absence and presence of 10 μM haloperidol, respectively. The data are shown as the mean ± SEM from three independent experiments carried out in duplicate. (E) Competitive binding of [3H](+)-pentazocine and the selective Sig1R agonist PRE-084 in membranes of SK-OV-3-Sig1R-YFP cells. The data are shown as the mean ± SEM from four independent experiments carried out in duplicate. ***p < 0.001 in comparison with SK-OV-3 cells.

For microscopy experiments, ≈24 h prior to imaging SK-OV-3 cells were seeded in 8-well glass-bottom imaging chambers (Zell Kontakt, Germany) at a density of 20 000–25 000 cells per well. Then the cells were transfected with appropriate BacMam baculoviruses (MOI ≈ 3), or FuGENE 6 transfection reagent was used for direct transfection. Plasmids of the markers of peroxisomes (mCherry-Peroxisomes-2), endosomes (mCherry-Endo-14), and lysosomes (mCherry-lysosomes-20) were a gift from Michael Davidson via Addgene (plasmids # 54520, # 55040 and # 55073, respectively). The marker of caveolae (Cav1-mRed) was a gift from Richard Pagano via Addgene (plasmid # 12681) [17]. Approximately 2 h prior to imaging, the culture medium was exchanged with photostable cell culture medium MEMO® with Supplement A (LiveLight™ products from Cell Guidance Systems).

Immunofluorescence assays

Cell fixation and permeabilization for all experiments with antibodies were performed according to the earlier published protocol [18]. 3% v/v Glyoxal (Sigma-Aldrich, Cat#: 128465) in 20% ethanol (pH was adjusted to 4,5 with glacial acetic acid (Sigma-Aldrich)) was used for fixation. SK-OV-3 cells, grown in 8-well glass-bottomed imaging chambers and transfected with Sig1R-YFP BacMam as described above, were fixed with Glyoxal solution, keeping cells on ice for 30 min and then at room temperature for an additional 30 min. Glyoxal was neutralized with 100 mM NH4Cl (20 min), and then the cells were permeabilized and blocked with 0.1% Triton X-100 and 2.5% BSA in PBS (15 min). For labeling of the mitochondrial outer membrane, anti-Tom20 (D8T4N)—rabbit mAb (Cell Signaling Technologies, Cat#: 42406) was used and anti-PDI (RL90)—mouse mAb, (Abcam, Cat#: ab2792) was used as an ER marker. Cells were incubated 60 min with 1:200 dilutions of primary antibodies in permeabilization/blocking solution and then washed three times for 5 min with the permeabilization/blocking solution. Then the cells were incubated for 60 min at room temperature with secondary antibodies (goat anti-rabbit (in case of anti-Tom20) or goat anti-mouse (in case of anti-PDI), both labeled abberior STAR RED (Abberior). Cells were washed 3 times for 5 min in PBS to remove unbound secondary antibodies and embedded in the Ibidi mounting medium (Ibidi, Cat#: 50001).

Preparation of membranes from SK-OV-3 cells

The membranes from SK-OV-3 cells with and without Sig1R-YFP were prepared as described earlier [19] with some modifications. The cells were transferred from culture dishes into Dulbecco’s PBS (2 mL per dish) and collected by centrifugation at 1000 ×g for 10 min at 4°C. The cell pellet was homogenized with a tissue homogenizer (Coleparmer Labgen 125) for 30 s in ice-cold buffer containing 5 mM Tris, 5 mM MgCl2, and Complete EDTA-free Protease Inhibitor Cocktail (Roche), pH = 7.4. The homogenate was then centrifuged at 35 000 ×g for 60 min at 4°C. The pellet was rehomogenized in ice-cold 50 mM Tris buffer with Complete EDTA-free Protease Inhibitor Cocktail (pH = 7.4) followed by second centrifugation at 35 000 ×g for 60 min at 4°C. The final membrane pellet was rehomogenized in ice-cold 50 mM Tris binding buffer with pH = 8.0 (final volume calculated to correspond to 5 million cells/ml), aliquoted (0.5 ml aliquots), and stored at -90°C. Protein concentrations were measured by the Lowry method with some modifications [20], using bovine serum albumin as the standard.

[3H](+)-pentazocine binding assay

The binding experiments were carried out in 96-well plate format in a final volume of 200 μL as described earlier [21] with some modifications. In all assays, 20 μL membrane suspension was added to wells containing 140 μL binding buffer and 20 μL of competitive ligand (different concentrations of PRE-084 or 10 μM haloperidol (nonspecific binding) or binding buffer (control)) and incubated for 10 min at room temperature. Then, 20 μL [3H](+)-pentazocine was added (to achieve a final concentration of 2 nM for competitive binding experiments and 0.28 to 36 nM for saturation binding curve), and samples were incubated for 180 min at 37°C with continuous shaking. The bound radioligands were collected by rapid vacuum filtration through Millipore GF/C filters (Merck Millipore, Billerica, USA) presoaked in 0.3% polyethyleneimine. The filters were washed three times with 0.25 ml of 10 mM Tris buffer (pH = 8.0, 4°C), and their radioactivity was measured with a Wallac MicroBeta TriLux liquid scintillation counter (PerkinElmer, Waltham, USA).

Super-Resolution Radial Fluctuations (SRRF) microscopy

Epifluorescence and Highly Inclined and Laminated Optical sheet (HILO, pseudo-TIR [22]) imaging was conducted using an inverted microscope built around a Till iMIC body (Till Photonics/FEI, Munich, Germany), equipped with UPLSAPO 4× (NA 0.13), 20× oil (NA 0.85), 60× water (NA 1.2) and TIRF APON 60× oil (NA 1.49) objective lenses (Olympus Corp., Tokyo, Japan). The microscope was equipped with an environmental chamber (Solent Scientific Limited, Portsmouth, UK) to maintain a temperature of 37°C with a 5% CO2 supply for live-cell imaging. The samples were excited with 488 nm, 515 nm or 638 nm PhoxX laser diodes (Omicron-Laserage, Rodgau, Germany) or 561 nm acousto-optically modulated DPSS laser Cobolt Jive (Cobolt,AB, Solna, Sweden) combined in the SOLE-6 light engine (Omicron-Laserage, Rodgau, Germany) and launched into a single-mode fiber. Laser excitation was sent to a 2D Yanus scan head, which along with a Polytrope galvanometric mirror (Till Photonics/FEI, Munich, Germany), was used to position the laser focal spot in the back focal plane of the objective lens for epifluorescence or 360-pseudo-TIR illumination. Typically, imaging was performed with an excitation intensity of ∼ 5 mW. Emission light in colocalization experiments was spectrally separated with a ZT488/561rpc polychromatic dichroic mirror (2.0 mm substrate, Chroma Technology, Bellows Falls, USA) and a 524/628 nm BrightLine dual-band bandpass filter (Semrock Inc., Rochester, USA). For Sig1R-YFP positive control experiments, live-cell and immunofluorescence experiments in fixed-cells, additionally filter cube with a ZT514/640rpc polychromatic dichroic mirror (2.0 mm substrate, Chroma Technology, Bellows Falls, USA) and ECFP/EYFP ET dual-band bandpass filter (59017m, Chroma Technology, Bellows Falls, USA) was used. In the emission path, an additional 2× magnification was provided by a TuCam two-camera adapter (Andor Technology, Belfast, UK). Light detection was performed using an iXon Ultra 897 EMCCD camera (Andor Technology, Belfast, UK) with an effective pixel size of 133 nm in the case of 60× objective lenses. The exposure time was held constant at 100 ms. The calibration of the microscope system and multichannel corrections were performed with a PSFcheck slide [23].

The diffraction-limited live-cell imaging experiments were performed at 37°C in 5% CO2 atmosphere using 515 nm laser for excitation. Once a region of interest (ROI) of SK-OV-3 cells with Sig1R-YFP was selected the imaging protocol in Live Acquisitions software (Till Photonics/FEI, Munich, Germany) was started, which included autofocusing steps and epifluorescence Z-stacks (20 frames, with 200 nm piezo-focusing increment) were taken every 5 min.

For SRRF experiments detecting colocalization of Sig1R-YFP (green channel) and different markers (red channel), fixed cells were used. Before the cells in the 8-well imaging chambers were fixed by using cold fixation medium containing 2% paraformaldehyde (PFA) and 0.2% glutaraldehyde (GA) in PBS (15 min at room temperature), they were incubated for 5 min with freshly prepared 0.1 M sodium borohydride solution in PBS, washed twice with PBS, and then kept at 4°C with 0.05% sodium azide in PBS supplemented with ProLong™ Live Antifade Reagent (Invitrogen™). For imaging, selected cells with comparable expression levels of both fluorescent proteins were used. For the detection of the influence of Sig1R activation, the cells were additionally treated before fixation for different time intervals with 100 nM (+)-pentazocine. Multichannel frames were acquired in time-lapse mode (100 frames) under HILO illumination with an exposure time of 100 ms and sequential switching between 488 nm and 561 nm lasers. The SRRF images were reconstructed (100 frames per time point, magnification: 5, temporal analysis set-tings: TRA). The resolution of images was estimated by calculating the FRC [24] using the NanoJ-SQUIRREL plugin [25] and by reconstructing the original dataset separated into two different stacks composed of odd or even images. Colocalization analysis on multi-channel SRRF images was performed with the Statistical Object Distance Analysis (SO-DA) workflow [26]. Spots for colocalization analysis were extracted using a wavelet spot detector. Threshold (red channel—over 10% of the whole intensity dynamic range) and a SODA search block was applied. Spot coupling was presented as the ratio of colocalized red channel spots with green channel spots (within an increasing maximum search distance) and the whole number of detected red spots. Intracellular colocalization was quantified by analyzing images of 8 or more cells (per time point) in at least two independent experiments.

Chemicals

Haloperidol (4-[4-(4-Chlorophenyl)-4-hydroxy-1-piperidyl]-1-(4-fluorophenyl)-butan-1-one) was purchased from Alfa Aesar, Karlsruhe, Germany. PRE-084 (2-(4-Morpholinethyl)-1-phenylcyclo-hexanecarboxylate hydrochloride) was purchased from Tocris Bioscience Bristol, UK. (+)-Pentazocine (2-dimethylallyl-5,9-dimethyl-2’-hydroxybenzomorphan) was a kind gift from Dr. C. Abate (University of Bari, Italy). [3H](+)-Pentazocine (specific activity 33.9 Ci/mmol) was purchased from American Radiolabeled Chemicals, St. Louis, MO, USA.

Results

[3H](+)-Pentazocine demonstrates high affinity binding in SK-OV-3-Sig1R-YFP cells

The Sig1R-YFP construct has been widely used as a model of Sig1R, and it is believed that it behaves similarly to endogenous, untagged Sig1R [6, 8]. Since Sig1R is an ER chaperone protein, in our study, we used SK-OV-3 cells, which demonstrate relatively small nuclei and a large ER membrane network. SK-OV-3 cells were transfected with Sig1R-YFP using the BacMam system. A MOI = 3 for BacMam viruses was found to be optimal for these studies, as it revealed Sig1R-YFP expression in SK-OV-3 cells at a good level for visualization (Fig 1B). Although naive SK-OV-3 cells express endogenous Sig1R, the binding studies showed negligible specific binding of [3H](+)-pentazocine (Fig 1C). We used a [3H](+)-pentazocine binding assay to describe the functionality of the expressed Sig1R construct. The transfection of SK-OV-3 cells with Sig1R-YFP using the BacMam system caused a more than a ten-fold increase in the specific binding of [3H](+)-pentazocine to these cell membranes (Fig 1C). In the case of naive cells, the nonspecific binding reached 60 ± 8% of the total binding, while in the case of the transfected cells, this value was only 12%. [3H](+)-pentazocine retained its high binding affinity for membranes of SK-OV-3-Sig1R-YFP cells, and revealed a binding curve of simple one step binding model R + L Δ RL, with a Kd = 24 ± 5 nM and receptor density Bmax = 11 ± 3 pmol/mg protein (Fig 1D, data S1A Table). The selective Sig1R agonist PRE-084 caused concentration-dependent inhibition of [3H](+)-pentazocine binding with a Ki value of 13 nM (Fig 1E, data S1B Table), which is similar to previously published data [27, 28].

Localization of Sig1R-YFP in the cells

As the BacMam system was effective for the transfection of Sig1R-YFP into SK-OV-3 cells, we also used it to detect the localization of Sig1R within the cells. Cell exposure to a 515 nm laser and measurement of epifluorescence at 540 nm revealed that most of the fluorescence emitted by Sig1R-YFP was located in the ER region surrounding the nucleus (Fig 2). TIRF imaging demonstrated that no Sig1R-YFP could be detected in the plasma membrane, and the expression in the peripheral areas of cells was low (Fig 2). The Sig1R agonist PRE-084 at a concentration of 10 μM, which have been found to be optimal for the activation of Sig1R [29, 30], did not cause substantial changes in the localization of Sig1R-YFP within the cells (Fig 2 and S1 Fig). No other agonist-dependent changes in Sig1R-YFP localization were detected.

Fig 2. Widefield fluorescence and TIRF images of Sig1R-YFP in SK-OV-3 cells after Sig1R activation with PRE-084.

Fig 2

SK-OV-3 cells in 8-well glass-bottom imaging chambers were transfected with recombinant BacMam baculoviruses of Sig1R-YFP (MOI = 3) 24 h before imaging. The imaging was performed on the microscope stage (heated at 37°C and supplemented with 5% CO2) using 60× oil (NA 1.49) objective lenses (Olympus Corp., Tokyo, Japan) and 515 nm laser for excitation. Images were taken before (Control) and 30 min after the application of the Sig1R agonist PRE-084 (10 μm, final concentration). Scale bar = 10 μm.

The resolution of conventional microscopic measurements did not allow us to detailly determine whether the activation of Sig1R-YFP with agonists alters its localization. As the changes were quite small and remained below the resolution limits of conventional microscopy, a super-resolution approach was proposed to provide additional information in this context. For precise localization of Sig1R in the cell, we used different fluorescent proteins as markers for specific cellular structures. For endosomes we used mCherry-Endo-14 (S2A Fig), for lysosomes—mCherry-lysosomes-20 (S2B Fig), for caveolae—Cav1-mRed (S2C Fig), for peroxisomes—mCherry-Peroxisomes-2 (S2D Fig), for mitochondria pmKate2-mito (S2E Fig, Fig 3A), and for vesicular ER—KDEL-mRFP (Fig 3B). Among these markers, only markers of mitochondria and the ER indicated the highest colocalization level with Sig1R-YFP (Fig 3E, S2E Fig and Fig 3F). This outcome was in good agreement with previous findings [12, 31], which demonstrated that Sig1R is located in subdomains of the ER that are in proximity to mitochondria.

Fig 3. Colocalization of Sig1R-YFP in SK-OV-3 cells with the markers pmKate2-mito and KDEL-mRFP.

Fig 3

SK-OV-3 cells expressing Sig1R-YFP and pmKate2-mito (A, C, E), or KDEL-mRFP (B, D, F) in 8-well glass-bottom imaging chambers were fixed with PFA and GA as described in the Materials and methods. Multichannel frames were acquired in time-laps mode (100 frames) under HILO illumination with an exposure time of 100 ms and sequential switching between 488 nm and 561 nm lasers with 60× oil (NA 1.49) objective lense (Olympus Corp., Tokyo, Japan). Panels E and F present SRRF images showing colocalization of Sig1R-YFP (green, C and D) with pmKate2-mito (red, A), or KDEL-mRFP (red, B), scale bar 10 μm. Square in the panel F indicates zoomed region of SRRF image (please see Fig 4A for more details).

Mapping the Sig1R-YFP localization with SRRF and analyzing the (+)-pentazocine effect on whole cells

We have used the SRRF with a highly inclined and laminated optical sheet (HILO) illumination fluorescence microscope, which is a fast graphics processing unit enabled by the ImageJ plugin and is generally capable of achieving resolutions better than 150 nm [11]. Implementation of this method for visualization of Sig1R-YFP resulted in a detailed and sharp image that allowed us to detect Sig1R localization more precisely in fixed SK-OV-3 cells (Fig 3C and 3D). As shown in the Fig 3C and 3D, Sig1R-YFP was not evenly distributed over the whole ER, and, as also demonstrated previously [12, 31], several significantly brighter cluster structures (spots, puncta) in some ER regions were detected.

SRRF enables imaging of Sig1R-YFP in live cells. However, this results in noticeably lower resolution (in our study, the minimal Fourier Ring Correlations (FRC) decreased almost two-fold) due to diffusion and movements that occur in living cells. Nevertheless, we were able to monitor the direct movement of Sig1R-YFP from the collected SRRF images (S1 Video), and the average velocity of the detected particles was 64 ± 21 nm/s. This is in good agreement with earlier studies, where the average velocity of the bidirectional movement of two GFP-labeled ER proteins was in the range of 70 nm/s [32].

The use of fixed cells in the experiments in which the dynamics of proteins are to be studied, required numerous prepared samples, and to obtain comparable results, all these samples of cells needed to express similar protein levels. As with conventional transient transfection, achieving equal expression is usually a challenging task; the BacMam bacu-lovirus transfection system [33] was used in addition to Sig1R-YFP for the marker proteins KDEL-mRFP and pmKate2-mito. The determination of the virus concentration for each protein enabled us to use an optimal MOI, which gave similar good expression of marker proteins in SK-OV-3 cells as it was achieved for Sig1R-YFP (Fig 1B). The use of fixed cells means that for each time point, separate measurements with separate samples must be performed. Individual samples are influenced by cells heterogeneity. However, imaging of fixed cells allowed us to avoid possible artifact associated with photobleaching and phototoxicity effects during multiple measurements or on-line monitoring, which often cause shadowing or lead to misinterpretation of the consequences of drug treatment.

By using two-color SRRF microscopy, we imaged cells coexpressing Sig1R-YFP receptors with different intracellular markers (S2 Fig). Among the studied markers, KDEL-mRFP, a marker of the ER, exhibit a pattern of spots (Fig 3B) most similar to that of Sig1R-YFP (Fig 3D). Implementation of SRRF analysis revealed that even though the high-intensity spots of these two proteins were very close to each other, they showed only partial overlap, and the majority of the "coupled" spots showed some small spatial shifts (Fig 3F, Fig 4A), which remain below the diffraction limit and could be detected with only super-resolution methods. These shifts were not unidirectional as they would be in the case of chromatic aberrations of microscopic systems. To quantify the distance between the coupled spots, we used the Statistical Object Distance Analysis (SODA) workflow [26]. Cells with a similar expression level of both fluorescent proteins were selected, and the YFP and RFP spots were localized with an automatic algorithm based on wavelet trans-formation of the image [34]. The spots at the same intensity level (ΔI < 10% of the full intensity dynamic range) were thresholded, and SODA was used to measure spot coupling within different search distances (Fig 4B). The spot coupling of Sig1R-YFP and KDEL-mRFP achieved a level of 40% in the range of 300 nm, and it did not substantially increase with the additional increase in the search distance (Fig 4B green symbols). Considerably lower spot coupling was found between Sig1R-YFP and pmKate2-mito, which remained at 15% level in the range of 300 nm, but it continued to increase with increased search distances (Fig 4B blue filled symbols) without a clear sign of stabilization. The spot coupling of Sig1R-YFP with the other intracellular markers studied (mCherry-Endo-14 for endosomes (S2A Fig), mCherry-lysosomes-20 for lysosomes (S2B Fig), Cav1-mRed for caveolae (S2C Fig) and mCherry-Peroxisomes-2 for peroxisomes (S2D Fig) remained below 10% within the 300 nm distance and could not be reliably detected. The Pearson’s correlation coefficients of these markers with Sig1R-YFP were for endosomes 0.14, lysosomes 0.15, caveolae 0.05, peroxisomes 0.03 and mitochondria 0.05, while for ER in the same super-resolution mode 0.26 (Fig 3F), but in diffraction-limited mode 0.79 (S4F Fig).

Fig 4. The spot coupling analysis.

Fig 4

(A) Zoomed SRRF image of Fig 3F indicating spot coupling of Sig1R-YFP and KDEL-mRFP, which were extracted using a wavelet spot detector and marked with circles (scale bar 1 μm). (B) Dependence of the level of spot coupling of Sig1R-YFP with KDEL-mRFP (green circles), KDEL-mRFP in the presence of 100 nM (+)-pentazocine (red circles), pmKate2-mito (blue filled circles), and Sig1R-YFP (positive control, black circles) on the search distance from the receptor. The spot coupling analysis was performed with SODA workflow [26], and were presented as the ratio of red channel spots that colocalize with green channel spots to the total number of detected red spots. (C) Change in the spot coupling of Sig1R-YFP with KDEL-mRFP over time after activation of the receptor with 100 nM (+)-pentazocine. The first data point on the x-axis (0 min) indicates the baseline measurement. Spot coupling was calculated at a search distance of 133 nm, which corresponded to 5 SRRF pixels. The data were taken from images with at least 8 or more cells from at least two independent experiments.

The relatively high colocalization of Sig1R-YFP with KDEL-mRFP enabled us to study the behavior of Sig1R upon its activation with an agonist. Treatment of cells with 100 nM (+)-pentazocine caused an apparent decrease in the spot coupling of the receptor with the marker (Fig 4B red symbols). The shift was evident at all search distances studied, and in the case of activated receptors, no clear saturating threshold was achieved even at a search distance of 400 nm. Although the effects detected were not very large, the time-dependent changes in colocalization could be detected using sufficient data from the numerous samples studied in different experiments. In these experiments, the cells were fixed for each time point, and images were taken and analyzed. On average, 8 frames were taken of every well, and these usually contained 1–2 cells per frame, having on average 1000 spot localizations per cell. Approximately 300 of these spots were over the intensity threshold, which means that the spot coupling of more than 3000 objects was analyzed for every experimental point. For all images used in the analysis, the minimal FRC, which is the resolution criterion for super-resolution microscopy, was in a range between 52 and 59 nm. As we previously observed, the treatment of cells with 100 nM (+)-pentazocine caused a decrease in the level of spot coupling at all distances studied (Fig 4B). For the kinetic analysis, we selected a distance of 5 SRRF pixels (133 nm, which corresponded to 1 pixel on images without super-resolution improvement). The spot coupling level without drug treatment within this search distance was approximately 25%, and this dropped more than 10% within 100 min after the addition of the drug (Fig 4C). This decrease was time-dependent and could be described by the single exponential decay equation, revealing the first-order rate constant (6.2 ± 2.6) × 10–4 s-1, corresponding to a half-life of 18.7 min (Fig 4C). To avoid artifacts and for validation of the assay, we also performed positive control experiments, where the spots of Sig1R-YFP in the same cells were re-imaged 1 min after the first image was taken, using a different set of filters and another laser. In this case, almost full coupling of Sig1R-YFP and Sig1R-YFP spots was achieved within a distance of 80 nm (Fig 4B open symbols).

Discussion

The existence of Sig1R was first proposed in the 1970s – 1980s [35, 36]. However, the molecular mechanisms of this receptor have not been fully elucidated [37]. Sig1R was cloned in 1996 [38], while the crystal structure of full-length human Sig1R was published in 2016 [39]. Very recently, it was shown that Sig1R is an ER-localized type II membrane protein [40]. Nevertheless, there is no consensus about the dynamics of Sig1R within the cell. On the other hand, there is quite a good consensus that Sig1R is an ER protein that acts as a molecular chaperone and forms cholesterol-enriched microdomains in the ER membrane [12, 31, 40]. However, most of the evidence regarding the dynamics of Sig1R obtained with different cell imaging techniques is indirect as dynamic changes occurring remain below the diffraction limit of light microscopy and therefore cannot be clearly characterized. This study established a method to detect and analyze the intracellular dynamics of Sig1R in live cells using super-resolution imaging microscopy, which allows for shifting the detection limit below the diffraction limit. As there are no suitable antibodies or fluorescent ligands available that would allow us to monitor the dynamics of Sig1R, we used receptors tagged with YFP and transfected SK-OV-3 cells using BacMam technology. Here we must consider that YFP is a relatively large tag for Sig1R, which may influence the behavior of the receptor within the cell. However, we showed with the radioligand binding assay that the ligand binding properties of Sig1R-YFP were not affected. In addition, Yano et al. demonstrated that C-terminal-tagged Sig1R constructs show a response to ligand-induced oligomerization that is similar to that of intact Sig1R constructs [41]. Therefore, the YFP tag on the C-terminus of Sig1R likely did not have a significant impact on the intracellular dynamics of the construct used in our study. To minimize the effects associated with receptor overexpression, we used BacMam transfection technology. The detailed protocol for virus production [42] and a precise virus titration method [16] enabled optimal expression of the protein for visualization (Fig 1B), but, at the same time, prevented the formation of protein aggregates into cytoplasmic inclusion bodies. At the same time, the number of [3H](+)-pentazocine binding sites did not exceed the rat liver level [43]. This outcome is important not only in the analysis of the receptors but also the marker proteins used to determine receptor localization.

To make a step further, we had to change the conventional experimental setup: we needed super-resolution to see small changes; we needed a detection method that would enable us to see rapid changes, but we also needed a stable system that minimized the natural diffusion of proteins. Combining these three counteracting tasks was not easy but was possible. There are several super-resolution microscopy methods available [9], and here, we used SRRF analysis [11], which is a super-resolution algorithm that analyzes radial and temporal fluorescence intensity fluctuations in an image sequence to generate a super‑resolution image for live-cell recordings. The signal-to-background ratio was improved by using HILO sheet illumination [22]. This setup enabled monitoring the movement of Sig1R-YFP (S1 Video) but did not allow simultaneous detection of multiple probes. Therefore, sampling was performed, and fixed cells activated at different time points with agonists were compared in this study. Nevertheless, sample heterogeneity (different transfections and probes) did not interfere with detection of the change in colocalization of Sig1R-YFP with KDEL-mRFP after treatment with the Sig1R agonist. Although the microscopy images suggested colocalization of Sig1R-YFP and pmKate2-mito; the more detailed analysis revealed that these proteins are located in proximity to each other. A recent study demonstrated similar observation that Sig1R-GFP in HEK293 cells stained with the mitochondrial marker TOM20 is in close opposition to mitochondria [12]. The spot coupling observed between Sig1R-YFP and pmKate2-mito was less than 5% at a distance of 100 nm, while it increased linearly with increasing distance (Fig 3H). In the case of KDEL-mRFP, the spot coupling at 100 nm was almost 20% and had the shape of a hyperbole with a maximum close to 60%, one half of which was achieved at a distance of 200 nm. Activation of Sig1R-YFP with agonist caused a substantial decrease in the coupling at all distances studied (Fig 4B red and green circles). The fact that we could monitor this process in time is of particular importance (Fig 4C). Although this is not the first report where the effect of activation of Sig1R has been directly monitored, this study demonstrates a model system that can be used to study live cell dynamics of Sig1R at a very high resolution. We acknowledge that it is merely the first step in characterizing Sig1R biochemistry and pharmacology dynamics. To date, Sig1R activity has been studied by using several high-affinity compounds and measuring dissociation from binding immunoglobulin protein (BiP also known as GRP78 or HSPA5) or evaluating the oligomerization state of Sig1R [28, 31]. However, there is no live-cell imaging assay available that could demonstrate the functional activity of the receptor or allow to study dynamic protein-protein interactions at high resolution. Of course, the assay can be modified to achieve conditions even more close to the natural and to achieve even higher resolution. The use of HaloTag [44], SNAP-Tags [45, 46] or other genetically encoded tags [47] instead of fluorescent proteins would open a wider possibilities to select fluorophores for colocalization studies and protein tracking. On the other side, the new generation fluorescent proteins like mEos4b would open possibilities to use single particle-tracking localization microscopy (sptPALM) [48] for more detailed translocation analyzes. The implementation of these and other maybe even more sophisticated methods remain for the further studies of Sig1R.

KDEL is a target peptide sequence in the C-terminal end of the amino acid structure of a protein that prevents a protein from being secreted from the ER [49]. Therefore, the peptide KDEL coupled to a fluorescent protein has been widely used as a marker of this organelle. It has been previously shown that GFP-KDEL is localized in both the vesicular sub-compartment and reticular structures of ER, while RFP-conjugated KDEL labels the vesicular sub-compartment of the ER [50]. The vesicular sub-compartment of the ER, also known as the mobile form of the ER, ER-derived punctate structure or ribosome-associated vesicles, forms direct contacts with mitochondria [51]. Mobile ER-derived compartments are thought to be responsible for the regulation of calcium signaling and mitochondrial function [51]. Sig1R has been demonstrated to localize at the MAM [12, 31] and regulate calcium transport from the ER to mitochondria through the inositol 1,4,5-trisphosphate receptor [31]. Sig1R agonist-induced disruption of ER microdomains and a decrease in the formation of Sig1R clusters were observed in a recent study [12]. Herein, as an example, we have shown that activation of Sig1R decreases its coupling with KDEL-mRFP, which can be measured as a time-dependent process. Conventional pharmacological studies require measurements of concentration dependences of numerous ligands, agonists, partial agonists, and antagonists to provide conclusions about the protein as a drug target. Here we present the proof of principle assay system, which has a real potential to study Sig1R intracellular dynamics and automatization of the imaging for increased throughput screening [52] will allow to evaluate the activity of novel compounds acting at Sig1R.

Sig1R has been reported to be an important drug target, but most of the numerous drugs and drug candidates, that bind Sig1R with moderate affinity also have different primary targets [53]. Among these candidates are compounds with antiviral activity against hepatitis C virus (HCV) [54, 55], and COV family viruses [56], including SARS-CoV-2 [57]. Sigma receptors are among the human proteins, that have been shown to directly interact with SARS-CoV-2 proteins, particularly with the rotavirus nonstructural protein NSP6 [57]. This protein is a rotavirus protein whose function has not yet been clearly determined, but it has been proposed to be directed to mitochondria [58]. At the same time, the regulators of Sig1R are among these few pharmacological agents displaying antiviral activity in SARS-CoV-2 [57]. Therefore, it has been proposed that efficient Sig1R modulators may have potent anti-SARS-CoV-2 activity [59]. Very recently, a clinical trial demonstrated that treatment with fluvoxamine reduced the need for hospitalization of patients with early diagnosed COVID-19 [60]. However, very limited number of methods are available to study Sig1R functionality. Further development and implementation of the approach described herein for the characterization of Sig1R dynamics and pharmacological studies would lead to the acquisition of novel perspectives on this particular drug target, which may have an essential impact on SARS-CoV-2 treatment.

In conclusion, this first quantitative description of Sig1R dynamics in cells suggests new perspectives into studies of this receptor. The use of super-resolution microscopy revealed that receptor activation initiates its translocation, but the direct target/acceptor of this movement needs to be found. Further development of the assay will lead to new possibilities for the evaluation of Sig1R-targeted drugs.

Supporting information

S1 Fig. Activity of PRE-084 on the localization of Sig1R-YFP in SK-OV-3 cells.

SK-OV-3 cells in 8-well glass-bottom imaging chambers were transfected with recombinant BacMam baculoviruses of Sig1R-YFP (MOI = 3) 24h before the imaging. The imaging was performed on the microscope stage heated at 37°C using 60× water (NA 1.2) objective lenses (Olympus Corp., Tokyo, Japan) and 515 nm laser for excitation. The images were taken before and 15 min and 30 min after the application of a Sig1R specific agonist PRE-084 (10 μM, final concentration) are presented as panels A, B, and C, respectively. Scale bar 20 μm.

(TIF)

S2 Fig. Representative zoomed SRRF images of the expression of Sig1R-YFP together with intracellular markers.

Sig1R-YFP (green) together with markers of endosomes (mCherry-Endo-14, red, (A)), lysosomes (mCherry-lysosomes-20, red, (B)), caveolae (Cav1-mRed, red, (C)), peroxisomes (mCherry-Peroxisomes-2, red (D)) and mitochondria (pmKate2-mito, red, (E)) in SK-OV-3 cells. Cells in 8-well glass-bottom imaging chambers were fixed with PFA and GA as described in the Materials and methods. Imaging of the expression of Sig1R-YFP and peroxisomes was performed in live-cells. Multichannel frames were acquired in time-laps mode (100 frames), under HILO illumination with an exposure time of 100 ms and sequential switching between 488 nm and 561 nm lasers with 60× oil (NA 1.49) objective lenses (Olympus Corp., Tokyo, Japan). Scale bar = 1 μm. The Pearson’s correlation coefficients with Sig1R-YFP were for endosomes 0.14 (A), lysosomes 0.15 (B), caveolae 0.05 (C), peroxisomes 0.03 (D) and mitochondria 0.05 (E), while for ER in the same super-resolution mode 0.26 (Fig 3F), but in diffraction-limited mode 0.79 (S4F Fig).

(TIF)

S3 Fig. Change of colocalization of Sig1R-YFP and KDEL-mRFP caused by (+)-pentazocine.

Colocalization demonstrated as spot coupling between Sig1R-YFP (green) and KDEL-mRFP (red) at baseline (Control, left image) and 100 min after activation of Sig1R with 100 nM (+)-pentazocine (right image). Zoomed SRRF images are presented. Multichannel frames were acquired in time-laps mode (100 frames), under HILO illumination with an exposure time of 100 ms and sequential switching between 488 nm and 561 nm lasers with 60× oil (NA 1.49) objective lenses (Olympus Corp., Tokyo, Japan). Scale bar = 1 μm. A time-dependent decrease in spot coupling was observed between Sig1R-YFP and KDEL-mRFP after activation of Sig1R with 100 nM (+)-pentazocine (middle image). The first data point on the x axis (0 min) indicates baseline measurement (Control). Spot coupling was calculated at a search distance of 133 nm, which corresponds to 5 SRRF pixels. Data are from images of at least 8 more cells from at least two independent experiments.

(TIF)

S4 Fig. Colocalization of Sig1R-YFP with immunostained ER and mitochondria on fixed and permeabilized SK-OV-3 cells.

Cells in 8-well glass-bottom imaging chambers were fixed with glyoxal and permeabilized with Triton X-100 as described in the Materials and methods. Sig1R-YFP were expressed with BacMam (green), and organelles were detected with markers of ER (anti-PDI primary antibody) (red in A, C, D, F) or mitochondria (anti-Tom20 primary antibody) (red in G, I, J, L) and visualized with secondary antibodies labeled with Abberior Star RED. Z-stacks were acquired (100 frames) under epi-illumination with an exposure time of 50 ms and sequential switching between 515 nm and 638 nm lasers with 60× oil (NA 1.49) objective lenses (Olympus Corp., Tokyo, Japan). Stacks were deconvolved with EpiDEMIC plugin [61]. Scale bar = 10 μm for images in (A, B, C, G, H, I) and 1 μm for images in (D, E, F, J, K, L).

(PNG)

S1 Table

(A) Specific binding of [3H](+)-pentazocine to membranes of SK-OV-3-Sig1R-YFP cells. (B) Displacement of [3H](+)-pentazocine binding to membranes of SK-OV-3-Sig1R-YFP cells by PRE-084.

(PDF)

S1 Video. Movement of the Sig1R-YFP in SK-OV-3 cells.

SK-OV-3 cells were seeded on 8-well glass-bottom imaging chambers (Zell Kontakt, Germany) at a density 20 000–25 000 cells per well 24 h before the imaging. Then the cells were transfected with Bac-Mam baculoviruses of Sig1R-YFP (MOI = 3) and 2 h before the imaging the culture medium was exchanged by photostable cell culture medium LiveLight™ MEMO. The imaging experiments were performed at 37°C in 5% CO2 atmosphere. After selection of ROI and adjustment of HILO illumination angle the videos were acquired using continuous illumination with 515 nm laser and 10 ms exposure time per frame. SRRF images were reconstructed using NanoJ-SRRF plugin (100 frames per time point [62], magnification: 5, temporal analysis settings: TRPPM). Bright fluorescent spots were automatically extracted using wavelet spot detector in Icy software [63] and tracked with spot tracking block which relies on Multiple Hypothesis Tracking algorithm [64] (motion mode: directed, optimization: LPsolver, filter out trajectories < 5 frames duration).

(MP4)

Acknowledgments

We thank Dr. Peter McCormick for the pcDNA3.1(+)-Sig1R-YFP plasmid and Dr. Erik L. Snapp for providing KDEL-mRFP construct.

Data Availability

All relevant data are within the manuscript and its Supporting Information files.

Funding Statement

SV- Estonian Research Council grant (PSG230) EV- European Regional Development Fund Project No. 1.1.1.2/VIAA/2/18/376 "Sigma chaperone protein as a novel drug target" AR, EV - COST action CA 18133 ERNEST. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

References

  • 1.Su TP, Hayashi T, Maurice T, Buch S, Ruoho AE. The sigma-1 receptor chaperone as an inter-organelle signaling modulator. Trends Pharmacol Sci. 2010;31(12):557–66. doi: 10.1016/j.tips.2010.08.007 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Su TP, Su TC, Nakamura Y, Tsai SY. The Sigma-1 Receptor as a Pluripotent Modulator in Living Systems. Trends Pharmacol Sci. 2016;37(4):262–78. Epub 2016/02/13. doi: 10.1016/j.tips.2016.01.003 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Balasuriya D, D’Sa L, Talker R, Dupuis E, Maurin F, Martin P, et al. A direct interaction between the sigma-1 receptor and the hERG voltage-gated K+ channel revealed by atomic force microscopy and homogeneous time-resolved fluorescence (HTRF(R)). J Biol Chem. 2014;289(46):32353–63. doi: 10.1074/jbc.M114.603506 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Mavlyutov TA, Yang H, Epstein ML, Ruoho AE, Yang J, Guo LW. APEX2-enhanced electron microscopy distinguishes sigma-1 receptor localization in the nucleoplasmic reticulum. Oncotarget. 2017;8(31):51317–30. doi: 10.18632/oncotarget.17906 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Abate C, Riganti C, Pati ML, Ghigo D, Berardi F, Mavlyutov T, et al. Development of sigma-1 (sigma1) receptor fluorescent ligands as versatile tools to study sigma1 receptors. Eur J Med Chem. 2016;108:577–85. doi: 10.1016/j.ejmech.2015.12.014 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Hayashi T, Su TP. Intracellular dynamics of σ-1 receptors (σ1 binding sites) in NG108-15 cells. J Pharmacol Exp Ther. 2003;306(2):726–33. Epub 2003/05/06. doi: 10.1124/jpet.103.051292 [DOI] [PubMed] [Google Scholar]
  • 7.Hayashi T, Su TP. Sigma-1 receptors at galactosylceramide-enriched lipid microdomains regulate oligodendrocyte differentiation. Proc Natl Acad Sci U S A. 2004;101(41):14949–54. doi: 10.1073/pnas.0402890101 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Wong AY, Hristova E, Ahlskog N, Tasse LA, Ngsee JK, Chudalayandi P, et al. Aberrant Subcellular Dynamics of Sigma-1 Receptor Mutants Underlying Neuromuscular Diseases. Mol Pharmacol. 2016;90(3):238–53. Epub 2016/07/16. doi: 10.1124/mol.116.104018 [DOI] [PubMed] [Google Scholar]
  • 9.Schermelleh L, Ferrand A, Huser T, Eggeling C, Sauer M, Biehlmaier O, et al. Super-resolution microscopy demystified. Nat Cell Biol. 2019;21(1):72–84. Epub 2019/01/04. doi: 10.1038/s41556-018-0251-8 [DOI] [PubMed] [Google Scholar]
  • 10.Min J, Vonesch C, Kirshner H, Carlini L, Olivier N, Holden S, et al. FALCON: fast and unbiased reconstruction of high-density super-resolution microscopy data. Sci Rep. 2014;4:4577. doi: 10.1038/srep04577 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Gustafsson N, Culley S, Ashdown G, Owen DM, Pereira PM, Henriques R. Fast live-cell conventional fluorophore nanoscopy with ImageJ through super-resolution radial fluctuations. Nature Commun. 2016;7:12471. doi: 10.1038/ncomms12471 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Zhemkov V, Ditlev JA, Lee W-R, Wilson M, Liou J, Rosen MK, et al. The role of sigma 1 receptor in organization of endoplasmic reticulum signaling microdomains. eLife. 2021;10:e65192. doi: 10.7554/eLife.65192 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Mazina O, Reinart-Okugbeni R, Kopanchuk S, Rinken A. BacMam system for FRET-based cAMP sensor expression in studies of melanocortin MC1 receptor activation. J Biomol Screen. 2012;17(8):1096–101. doi: 10.1177/1087057112449862 [DOI] [PubMed] [Google Scholar]
  • 14.Navarro G, Moreno E, Aymerich M, Marcellino D, McCormick PJ, Mallol J, et al. Direct involvement of sigma-1 receptors in the dopamine D1 receptor-mediated effects of cocaine. Proc Natl Acad Sci U S A. 2010;107(43):18676–81. Epub 2010/10/20. doi: 10.1073/pnas.1008911107 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Snapp EL, Sharma A, Lippincott-Schwartz J, Hegde RS. Monitoring chaperone engagement of substrates in the endoplasmic reticulum of live cells. Proc Natl Acad Sci U S A. 2006;103(17):6536–41. doi: 10.1073/pnas.0510657103 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Laasfeld T, Kopanchuk S, Rinken A. Image-based cell-size estimation for baculovirus quantification. Biotechniques. 2017;63(4):161–8. Epub 2017/10/20. doi: 10.2144/000114595 [DOI] [PubMed] [Google Scholar]
  • 17.Sharma DK, Brown JC, Choudhury A, Peterson TE, Holicky E, Marks DL, et al. Selective stimulation of caveolar endocytosis by glycosphingolipids and cholesterol. Mol Biol Cell. 2004;15(7):3114–22. Epub 2004/04/27. doi: 10.1091/mbc.e04-03-0189 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Richter KN, Revelo NH, Seitz KJ, Helm MS, Sarkar D, Saleeb RS, et al. Glyoxal as an alternative fixative to formaldehyde in immunostaining and super-resolution microscopy. EMBO J. 2018;37(1):139–59. doi: 10.15252/embj.201695709 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Reinart-Okugbeni R, Ausmees K, Kriis K, Werner F, Rinken A, Kanger T. Chemoenzymatic synthesis and evaluation of 3-azabicyclo[3.2.0]heptane derivatives as dopaminergic ligands. Eur J Med Chem. 2012;55(1768–3254 (Electronic)):255–61. doi: 10.1016/j.ejmech.2012.07.025 [DOI] [PubMed] [Google Scholar]
  • 20.Peterson GL. Determination of total protein. Methods Enzymol. 1983;91:95–119. doi: 10.1016/s0076-6879(83)91014-5 [DOI] [PubMed] [Google Scholar]
  • 21.Lee IT, Chen S, Schetz JA. An unambiguous assay for the cloned human sigma1 receptor reveals high affinity interactions with dopamine D4 receptor selective compounds and a distinct structure-affinity relationship for butyrophenones. Eur J Pharmacol. 2008;578(2–3):123–36. doi: 10.1016/j.ejphar.2007.09.020 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Tokunaga M, Imamoto N, Sakata-Sogawa K. Highly inclined thin illumination enables clear single-molecule imaging in cells. Nature Meth. 2008;5:159–61. doi: 10.1038/nmeth1171 [DOI] [PubMed] [Google Scholar]
  • 23.Corbett AD, Shaw M, Yacoot A, Jefferson A, Schermelleh L, Wilson T, et al. Microscope calibration using laser written fluorescence. Opt Express. 2018;26(17):21887–99. Epub 2018/08/23. doi: 10.1364/OE.26.021887 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Nieuwenhuizen RP, Lidke KA, Bates M, Puig DL, Grunwald D, Stallinga S, et al. Measuring image resolution in optical nanoscopy. Nature Meth. 2013;10(6):557–62. Epub 2013/04/30. doi: 10.1038/nmeth.2448 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.Culley S, Albrecht D, Jacobs C, Pereira PM, Leterrier C, Mercer J, et al. Quantitative mapping and minimization of super-resolution optical imaging artifacts. Nature Meth. 2018;15(4):263–6. doi: 10.1038/nmeth.4605 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.Lagache T, Grassart A, Dallongeville S, Faklaris O, Sauvonnet N, Dufour A, et al. Mapping molecular assemblies with fluorescence microscopy and object-based spatial statistics. Nature Commun. 2018;9(1):698. Epub 2018/02/17. doi: 10.1038/s41467-018-03053-x [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Zvejniece L, Vavers E, Svalbe B, Vilskersts R, Domracheva I, Vorona M, et al. The cognition-enhancing activity of E1R, a novel positive allosteric modulator of sigma-1 receptors. Br J Pharmacol. 2014;171(3):761–71. Epub 2014/02/05. doi: 10.1111/bph.12506 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28.Yano H, Bonifazi A, Xu M, Guthrie DA, Schneck SN, Abramyan AM, et al. Pharmacological profiling of sigma 1 receptor ligands by novel receptor homomer assays. Neuropharmacol. 2018;133:264–75. Epub 2018/02/07. doi: 10.1016/j.neuropharm.2018.01.042 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.Jiang L, Cui J, Zhang C, Xie J, Zhang S, Fu D, et al. Sigma-1 receptor is involved in diminished ovarian reserve possibly by influencing endoplasmic reticulum stress-mediated granulosa cells apoptosis. Aging. 2020;12(10):9041–65. doi: 10.18632/aging.103166 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30.Martin P, de Witte PAM, Maurice T, Gammaitoni A, Farfel G, Galer B. Fenfluramine acts as a positive modulator of sigma-1 receptors. Epilepsy Behav. 2020;105:106989. doi: 10.1016/j.yebeh.2020.106989 [DOI] [PubMed] [Google Scholar]
  • 31.Hayashi T, Su TP. Sigma-1 receptor chaperones at the ER-mitochondrion interface regulate Ca2+ signaling and cell survival. Cell. 2007;131(3):596–610. doi: 10.1016/j.cell.2007.08.036 [DOI] [PubMed] [Google Scholar]
  • 32.Aihara Y, Inoue T, Tashiro T, Okamoto K, Komiya Y, Mikoshiba K. Movement of endoplasmic reticulum in the living axon is distinct from other membranous vesicles in its rate, form, and sensitivity to microtubule inhibitors. J Neurosci Res. 2001;65(3):236–46. doi: 10.1002/jnr.1147 [DOI] [PubMed] [Google Scholar]
  • 33.Mazina O, Allikalt A, Heinloo A, Reinart-Okugbeni R, Kopanchuk S, Rinken A. cAMP Assay for GPCR Ligand Characterization: Application of BacMam Expression System. Methods Mol Biol. 2015;1272:65–77. doi: 10.1007/978-1-4939-2336-6_5 [DOI] [PubMed] [Google Scholar]
  • 34.Toufik B, Mokhtar N. The Wavelet Transform for Image Processing Applications. Advances in Wavelet Theory and Their Applications in Engineering, Physics and Technology. 2012. doi: 10.5772/35982 [DOI] [Google Scholar]
  • 35.Martin WR, Eades CG, Thompson JA, Huppler RE, Gilbert PE. The effects of morphine- and nalorphine- like drugs in the nondependent and morphine-dependent chronic spinal dog. J Pharmacol Exp Ther. 1976;197(3):517. [PubMed] [Google Scholar]
  • 36.Su TP. Evidence for sigma opioid receptor: binding of [3H]SKF-10047 to etorphine-inaccessible sites in guinea-pig brain. J Pharmacol Exp Ther. 1982;223(2):284. [PubMed] [Google Scholar]
  • 37.Schmidt HR, Kruse AC. The Molecular Function of sigma Receptors: Past, Present, and Future. Trends Pharmacol Sci. 2019;40(9):636–54. Epub 2019/08/08. doi: 10.1016/j.tips.2019.07.006 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 38.Hanner M, Moebius FF, Flandorfer A, Knaus HG, Striessnig J, Kempner E, et al. Purification, molecular cloning, and expression of the mammalian sigma1-binding site. Proceedings of the National Academy of Sciences. 1996;93(15):8072. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 39.Schmidt HR, Zheng S, Gurpinar E, Koehl A, Manglik A, Kruse AC. Crystal structure of the human sigma1 receptor. Nature. 2016;532(7600):527–30. Epub doi: 10.1038/nature17391 . [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 40.Sharma N, Patel C, Shenkman M, Kessel A, Ben-Tal N, Lederkremer GZ. The Sigma-1 receptor is an ER-localized type II membrane protein. J Biol Chem. 2021;297(5). doi: 10.1016/j.jbc.2021.101299 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 41.Yano H, Liu L, Naing S, Shi L. The Effects of Terminal Tagging on Homomeric Interactions of the Sigma 1 Receptor. Front Neurosci. 2019;13:1356. Epub 2020/01/11. doi: 10.3389/fnins.2019.01356 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 42.Lavogina D, Laasfeld T, Tahk MJ, Kukk O, Allikalt A, Kopanchuk S, et al. cAMP Biosensor Assay Using BacMam Expression System: Studying the Downstream Signaling of LH/hCG Receptor Activation. Methods Mol Biol. 2268. 2021/06/05 ed2021. p. 179–92. doi: 10.1007/978-1-0716-1221-7_12 [DOI] [PubMed] [Google Scholar]
  • 43.Hong WC. Distinct Regulation of σ1 Receptor Multimerization by Its Agonists and Antagonists in Transfected Cells and Rat Liver Membranes. J Pharmacol Exp Ther. 2020;373(2):290–301. doi: 10.1124/jpet.119.262790 [DOI] [PubMed] [Google Scholar]
  • 44.Los GV, Encell LP, McDougall MG, Hartzell DD, Karassina N, Zimprich C, et al. HaloTag: A Novel Protein Labeling Technology for Cell Imaging and Protein Analysis. ACS Chem Biol. 2008;3(6):373–82. doi: 10.1021/cb800025k [DOI] [PubMed] [Google Scholar]
  • 45.Keppler A, Pick H, Arrivoli C, Vogel H, Johnsson K. Labeling of fusion proteins with synthetic fluorophores in live cells. Proceedings of the National Academy of Sciences. 2004;101(27):9955–9. doi: 10.1073/pnas.0401923101 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 46.Hoelzel CA, Zhang X. Visualizing and Manipulating Biological Processes by Using HaloTag and SNAP-Tag Technologies. Chembiochem. 2020;21(14):1935–46. doi: 10.1002/cbic.202000037 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 47.van Unen J, Woolard J, Rinken A, Hoffmann C, Hill SJ, Goedhart J, et al. A Perspective on Studying G-Protein-Coupled Receptor Signaling with Resonance Energy Transfer Biosensors in Living Organisms. Mol Pharmacol. 2015;88(3):589–95. Epub 2015/05/15. doi: 10.1124/mol.115.098897 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 48.De Zitter E, Thédié D, Mönkemöller V, Hugelier S, Beaudouin J, Adam V, et al. Mechanistic investigation of mEos4b reveals a strategy to reduce track interruptions in sptPALM. Nature Meth. 2019;16(8):707–10. doi: 10.1038/s41592-019-0462-3 [DOI] [PubMed] [Google Scholar]
  • 49.Denecke J, De Rycke R, Botterman J. Plant and mammalian sorting signals for protein retention in the endoplasmic reticulum contain a conserved epitope. EMBO J. 1992;11(6):2345–55. doi: 10.1002/j.1460-2075.1992.tb05294.x [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 50.Bannai H, Inoue T, Nakayama T, Hattori M, Mikoshiba K. Kinesin dependent, rapid, bi-directional transport of ER sub-compartment in dendrites of hippocampal neurons. J Cell Sci. 2004;117(Pt 2):163–75. Epub 2003/12/17. doi: 10.1242/jcs.00854 [DOI] [PubMed] [Google Scholar]
  • 51.Carter SD, Hampton CM, Langlois R, Melero R, Farino ZJ, Calderon MJ, et al. Ribosome-associated vesicles: A dynamic subcompartment of the endoplasmic reticulum in secretory cells. Sci Adv. 2020;6(14):eaay9572. Epub 2020/04/10. doi: 10.1126/sciadv.aay9572 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 52.Laasfeld T, Ehrminger R, Tahk MJ, Veiksina S, Kolvart KR, Min M, et al. Budded baculoviruses as a receptor display system to quantify ligand binding with TIRF microscopy. Nanoscale. 2021;13:2436–47. doi: 10.1039/d0nr06737g [DOI] [PubMed] [Google Scholar]
  • 53.Vela JM. Repurposing Sigma-1 Receptor Ligands for COVID-19 Therapy? Front Pharmacol. 2020;11:1716. doi: 10.3389/fphar.2020.582310 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 54.Friesland M, Mingorance L, Chung J, Chisari FV, Gastaminza P. Sigma-1 receptor regulates early steps of viral RNA replication at the onset of hepatitis C virus infection. J Virol. 2013;87(0022-538X (Linking)):6377–90. doi: 10.1128/JVI.03557-12 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 55.Gastaminza P, Whitten-Bauer C, Chisari FV. Unbiased probing of the entire hepatitis C virus life cycle identifies clinical compounds that target multiple aspects of the infection. Proc Natl Acad Sci U S A. 2010;107(0027–8424 (Linking)):291–6. doi: 10.1073/pnas.0912966107 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 56.Dyall J, Coleman CM, Hart BJ, Venkataraman T, Holbrook MR, Kindrachuk J, et al. Repurposing of clinically developed drugs for treatment of Middle East respiratory syndrome coronavirus infection. AntimicrobAgents Chemother. 2014;58(0066–4804 (Linking)):4885–93. doi: 10.1128/AAC.03036-14 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 57.Gordon DE, Jang GM, Bouhaddou M, Xu J, Obernier K, White KM, et al. A SARS-CoV-2 protein interaction map reveals targets for drug repurposing. Nature. 2020;583(7816):459–68. Epub 2020/05/01. doi: 10.1038/s41586-020-2286-9 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 58.Holloway G, Johnson RI, Kang Y, Dang VT, Stojanovski D, Coulson BS. Rotavirus NSP6 localizes to mitochondria via a predicted N-terminal a-helix. J Gen Virol. 2015;96(0022–1317 (Linking)):3519–24. doi: 10.1099/jgv.0.000294 [DOI] [PubMed] [Google Scholar]
  • 59.Abate C, Niso M, Abatematteo FS, Contino M, Colabufo NA, Berardi F. PB28, the Sigma-1 and Sigma-2 Receptors Modulator With Potent Anti-SARS-CoV-2 Activity: A Review About Its Pharmacological Properties and Structure Affinity Relationships. Front Pharmacol. 2020;11(1663–9812 (Linking)):589810. doi: 10.3389/fphar.2020.589810 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 60.Reis G, dos Santos Moreira-Silva EA, Silva DCM, Thabane L, Milagres AC, Ferreira TS, et al. Effect of early treatment with fluvoxamine on risk of emergency care and hospitalisation among patients with COVID-19: the TOGETHER randomised, platform clinical trial. The Lancet Global Health. doi: 10.1016/S2214-109X(21)00448-4 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 61.Soulez F, Denis L, Tourneur Y, É T, editors. Blind deconvolution of 3D data in wide field fluorescence microscopy. 2012 9th IEEE International Symposium on Biomedical Imaging (ISBI); 2012 2–5 May 2012.
  • 62.Laine RF, Tosheva KL, Gustafsson N, Gray RDM, Almada P, Albrecht D, et al. NanoJ: a high-performance open-source super-resolution microscopy toolbox. J Phys D Appl Phys. 2019;52(16):163001. Epub 2019/04/17. doi: 10.1088/1361-6463/ab0261 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 63.de Chaumont F, Dallongeville S, Chenouard N, Herve N, Pop S, Provoost T, et al. Icy: an open bioimage informatics platform for extended reproducible research. Nat Methods. 2012;9(7):690–6. Epub 2012/06/30. doi: 10.1038/nmeth.2075 [DOI] [PubMed] [Google Scholar]
  • 64.Chenouard N, Bloch I, Olivo-Marin JC. Multiple hypothesis tracking for cluttered biological image sequences. IEEE Trans Pattern Anal Mach Intell. 2013;35(11):2736–3750. Epub 2013/09/21. doi: 10.1109/TPAMI.2013.97 [DOI] [PubMed] [Google Scholar]

Decision Letter 0

Jean-Pierre Mothet

4 Mar 2022

PONE-D-21-39296Intracellular dynamics of the Sigma-1 receptor observed with super-resolution imaging microscopyPLOS ONE

Dear Dr. Rinken,

Thank you for submitting your manuscript to PLOS ONE. We have now  received the reviews of two independent experts. It took some time to find suitable reviewers and I am sorry for the long delay in contacting you. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

 Although both reviewers and myself found the study well performed and of interest, reviewers raised particular concerns that should be addressed before acceptance. Based on their reports, I notably invite you  to show that Sig1R-YFP is indeed functional and to perform an depth co localization analysis for confirming its presence in the ER.  I also recommend to show that localisation of Sig-1R-YFP is similar/equal to that of endogenous Sig-1Rs.Please submit your revised manuscript by Apr 18 2022 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols.

We look forward to receiving your revised manuscript.

Kind regards,

Jean-Pierre Mothet, Ph.D

Academic Editor

PLOS ONE

Journal Requirements:

When submitting your revision, we need you to address these additional requirements.

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf  and

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

2. Thank you for stating the following financial disclosure:

“SV- Estonian Research Council grant (PSG230)

EV- European Regional Development Fund Project No. 1.1.1.2/VIAA/2/18/376 "Sigma chaperone protein as a novel drug target"

AR, EV - COST action CA 18133 ERNEST”

Please state what role the funders took in the study.  If the funders had no role, please state: "The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript."

If this statement is not correct you must amend it as needed.

Please include this amended Role of Funder statement in your cover letter; we will change the online submission form on your behalf.

3. In your Data Availability statement, you have not specified where the minimal data set underlying the results described in your manuscript can be found. PLOS defines a study's minimal data set as the underlying data used to reach the conclusions drawn in the manuscript and any additional data required to replicate the reported study findings in their entirety. All PLOS journals require that the minimal data set be made fully available. For more information about our data policy, please see http://journals.plos.org/plosone/s/data-availability.

Upon re-submitting your revised manuscript, please upload your study’s minimal underlying data set as either Supporting Information files or to a stable, public repository and include the relevant URLs, DOIs, or accession numbers within your revised cover letter. For a list of acceptable repositories, please see http://journals.plos.org/plosone/s/data-availability#loc-recommended-repositories. Any potentially identifying patient information must be fully anonymized.

Important: If there are ethical or legal restrictions to sharing your data publicly, please explain these restrictions in detail. Please see our guidelines for more information on what we consider unacceptable restrictions to publicly sharing data: http://journals.plos.org/plosone/s/data-availability#loc-unacceptable-data-access-restrictions. Note that it is not acceptable for the authors to be the sole named individuals responsible for ensuring data access.

We will update your Data Availability statement to reflect the information you provide in your cover letter.

4. Please review your reference list to ensure that it is complete and correct. If you have cited papers that have been retracted, please include the rationale for doing so in the manuscript text, or remove these references and replace them with relevant current references. Any changes to the reference list should be mentioned in the rebuttal letter that accompanies your revised manuscript. If you need to cite a retracted article, indicate the article’s retracted status in the References list and also include a citation and full reference for the retraction notice.

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

Reviewer #2: Yes

**********

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

Reviewer #2: No

**********

3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: No

**********

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: Yes

**********

5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: Sergei Kopanchuk et al examined intracellular dynamics of the sigma-1 receptor (Sig-1R) by using the super-resolution imaging microscopy.

The Sig-1R has been proposed as a novel therapeutic target of several human diseases such as neurodegenerative disorders, drug abuse, and virus infection. The unique cell biological properties include: (1) Sig-1Rs form clusters at endoplasmic reticulum (ER) subdomains and (2) translocate upon activation by Sig-1R agonists. However, detailed characterization of subcellular localization and dynamics of Sig-1Rs wait further investigations. The technical barriers against the characterization include (1) the transfection technique which is essential for live-cell imaging may alter properties or location of the protein, especially when expressed at the ER membrane; (2) only a small portion of Sig-1Rs translocate upon their activation; (3) since Sig-1Rs move mainly on the ER membrane with a limited distance (not organelle-to-organelle translocation), high resolution is required (higher than that of conventional confocal microscopy).

Kopanchuk et al overcome a few above-mentioned barriers. They used SRRF to detect and analyze the intracellular dynamics of Sig1R. They also employed BacMam technology which was optimized to avoid the generation of protein aggregates and achieve equal expression in the majority of cells

SRRF with SODA experiments not only confirms the previously suggested Sig-1R localization (co-localization with both ER and mitochondoria markers), but also provide convincing data; namely, even though the high-intensity spots of these proteins are very close to each other, they only partially overlap, and locate within the distance of 100 nm. More importantly SRRF enables the quantitative measurement of Sig-1R agonist-induced translocation and average velocity.

The manuscript was well written and provided data should be important for a wide range of scientists (i.e., in the fields of cell biology, molecular biology and pharmacology). The experimental design, used technologies, data analyses, and data interpretation are all reasonable and scientifically sound.

Having said this, I would like to provide a few suggestions to increase the quality of the paper.

1. Figure 3 includes the most important data, but its resolution is not high enough (This problem might be caused by its conversion to pdf during the processing of the submission). Please increase the quality of the image.

2. It may be important to provide data that suggests the subcellular Sig-1R-YFP is similar/equal to that of endogenous Sig-1Rs. The subcellular membrane fractionation followed by western blotting should answer to this question.

Reviewer #2: Major Comments

1. The previous authors who verified that Sig1R tagging with YFP did not render it non-functional tested it in NG108-15 cells (Hayashi & Su, J Pharmacol Exp Ther, 2003) and MEF cells (Wong et al., Mol Pharmacol. 2016). Can the authors provide evidence that this same tagging does not alter function in SK-OV-3 cells?

2. As shown in figure1B, there is little specific binding for endogenous Sig1R by pentazocine. Does this mean the endogenous Sig1R is non-functional? If it is functional, why does the Sig1R-YFP binding show an order of magnitude about 9 times that of the endogenous?

3. The authors should re-work Figure2. If these are fixed cells, then it needs to show at least DAPI stained nuclei as well as ER, mitochondria or Golgi stained cells. Provide the merged imaged for these different stains in addition to the Sig1R-YFP fluorescent cells.

The current data doesn’t prove that Sig1R-YFP is localised to the ER. It could be simply cytoplasmic localised without preference of the ER. A colocalization analysis is the minimum needed to verify its association with other cellular organelles in this data.

4. The authors should provide a Pearson’s correlation co-localisation analysis for Fig S2. This is absolutely essential!

5. The authors should consider the merits of doing single molecule imaging with Sig1R tagged to wither Halo or mEos. This should be mentioned in the discussion segment.

Minor Comments

1. The authors should provide a more detailed data for the expression of Sig1R-YFP than what is shown in Fig.1A. Consider providing confocal images taken on a 63X of 100X objective with some nuclear and ER immunolabelling.

2. The authors should provide a schema of the (pentazocine) binding assay before showing Fig.1B. It is a bit jarring. Also, the authors should provide raw data of the binding assay done on the naïve cells, Sig1R-YFP expressing cells and the PRE-084 treated cells (graphs). Make it a supplementary to Fig.1C & D.

3. The authors should consider using a 100X Obj in TIRF configuration to verify absence of Sig1R-YFP. Also the data will be more convincing if the authors label the cell with Sig1 tagged with multiple tags, for example, GFP and mCherry/mRuby and show by TIRF imaging that these are also not localised to the plasma membrane.

4. Are the cells treated with PRE-084 the same as in the control images? If yes, it seems PRE-084 has effects in shrinking the cell.

5. In line 273, the authors should provide a reference where 10 µM of PRE-084 was used. If no reference is available, then the authors should provide a concentration gradient data, for example, 0 -150 uM with time showing the (absence/presence) of effect PRE-084 on Sig1-YFP in these cells.

6. The authors should re-word lines 290 – 293, such that it ends with Fig S2D) instead of Fig S2C).

7. The authors should consider placing the colour scheme naming in Fig.3H and not only place this information inside the figure legend.

**********

6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: Yes: Teruo Hayashi

Reviewer #2: No

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

PLoS One. 2022 May 18;17(5):e0268563. doi: 10.1371/journal.pone.0268563.r002

Author response to Decision Letter 0


27 Apr 2022

Dear Editor, dear reviewers,

Thank you very much for the effort, kind words, and useful and insightful suggestions. We have discussed the suggestions with all the authors and formulated answers and performed changes in the manuscript, which are described in detail in the file "Response_to_reviewers_REV1" uploaded to the Editorial Manager.

Attachment

Submitted filename: Response_to_reviewers_REV1.docx

Decision Letter 1

Jean-Pierre Mothet

3 May 2022

Intracellular dynamics of the Sigma-1 receptor observed with super-resolution imaging microscopy

PONE-D-21-39296R1

Dear Dr. Rinken,

We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at http://www.editorialmanager.com/pone/, click the 'Update My Information' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

Kind regards,

Jean-Pierre Mothet, Ph.D

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Reviewers' comments:

Acceptance letter

Jean-Pierre Mothet

10 May 2022

PONE-D-21-39296R1

Intracellular dynamics of the Sigma-1 receptor observed with super-resolution imaging microscopy

Dear Dr. Rinken:

I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact onepress@plos.org.

If we can help with anything else, please email us at plosone@plos.org.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr Jean-Pierre Mothet

Academic Editor

PLOS ONE

Associated Data

    This section collects any data citations, data availability statements, or supplementary materials included in this article.

    Supplementary Materials

    S1 Fig. Activity of PRE-084 on the localization of Sig1R-YFP in SK-OV-3 cells.

    SK-OV-3 cells in 8-well glass-bottom imaging chambers were transfected with recombinant BacMam baculoviruses of Sig1R-YFP (MOI = 3) 24h before the imaging. The imaging was performed on the microscope stage heated at 37°C using 60× water (NA 1.2) objective lenses (Olympus Corp., Tokyo, Japan) and 515 nm laser for excitation. The images were taken before and 15 min and 30 min after the application of a Sig1R specific agonist PRE-084 (10 μM, final concentration) are presented as panels A, B, and C, respectively. Scale bar 20 μm.

    (TIF)

    S2 Fig. Representative zoomed SRRF images of the expression of Sig1R-YFP together with intracellular markers.

    Sig1R-YFP (green) together with markers of endosomes (mCherry-Endo-14, red, (A)), lysosomes (mCherry-lysosomes-20, red, (B)), caveolae (Cav1-mRed, red, (C)), peroxisomes (mCherry-Peroxisomes-2, red (D)) and mitochondria (pmKate2-mito, red, (E)) in SK-OV-3 cells. Cells in 8-well glass-bottom imaging chambers were fixed with PFA and GA as described in the Materials and methods. Imaging of the expression of Sig1R-YFP and peroxisomes was performed in live-cells. Multichannel frames were acquired in time-laps mode (100 frames), under HILO illumination with an exposure time of 100 ms and sequential switching between 488 nm and 561 nm lasers with 60× oil (NA 1.49) objective lenses (Olympus Corp., Tokyo, Japan). Scale bar = 1 μm. The Pearson’s correlation coefficients with Sig1R-YFP were for endosomes 0.14 (A), lysosomes 0.15 (B), caveolae 0.05 (C), peroxisomes 0.03 (D) and mitochondria 0.05 (E), while for ER in the same super-resolution mode 0.26 (Fig 3F), but in diffraction-limited mode 0.79 (S4F Fig).

    (TIF)

    S3 Fig. Change of colocalization of Sig1R-YFP and KDEL-mRFP caused by (+)-pentazocine.

    Colocalization demonstrated as spot coupling between Sig1R-YFP (green) and KDEL-mRFP (red) at baseline (Control, left image) and 100 min after activation of Sig1R with 100 nM (+)-pentazocine (right image). Zoomed SRRF images are presented. Multichannel frames were acquired in time-laps mode (100 frames), under HILO illumination with an exposure time of 100 ms and sequential switching between 488 nm and 561 nm lasers with 60× oil (NA 1.49) objective lenses (Olympus Corp., Tokyo, Japan). Scale bar = 1 μm. A time-dependent decrease in spot coupling was observed between Sig1R-YFP and KDEL-mRFP after activation of Sig1R with 100 nM (+)-pentazocine (middle image). The first data point on the x axis (0 min) indicates baseline measurement (Control). Spot coupling was calculated at a search distance of 133 nm, which corresponds to 5 SRRF pixels. Data are from images of at least 8 more cells from at least two independent experiments.

    (TIF)

    S4 Fig. Colocalization of Sig1R-YFP with immunostained ER and mitochondria on fixed and permeabilized SK-OV-3 cells.

    Cells in 8-well glass-bottom imaging chambers were fixed with glyoxal and permeabilized with Triton X-100 as described in the Materials and methods. Sig1R-YFP were expressed with BacMam (green), and organelles were detected with markers of ER (anti-PDI primary antibody) (red in A, C, D, F) or mitochondria (anti-Tom20 primary antibody) (red in G, I, J, L) and visualized with secondary antibodies labeled with Abberior Star RED. Z-stacks were acquired (100 frames) under epi-illumination with an exposure time of 50 ms and sequential switching between 515 nm and 638 nm lasers with 60× oil (NA 1.49) objective lenses (Olympus Corp., Tokyo, Japan). Stacks were deconvolved with EpiDEMIC plugin [61]. Scale bar = 10 μm for images in (A, B, C, G, H, I) and 1 μm for images in (D, E, F, J, K, L).

    (PNG)

    S1 Table

    (A) Specific binding of [3H](+)-pentazocine to membranes of SK-OV-3-Sig1R-YFP cells. (B) Displacement of [3H](+)-pentazocine binding to membranes of SK-OV-3-Sig1R-YFP cells by PRE-084.

    (PDF)

    S1 Video. Movement of the Sig1R-YFP in SK-OV-3 cells.

    SK-OV-3 cells were seeded on 8-well glass-bottom imaging chambers (Zell Kontakt, Germany) at a density 20 000–25 000 cells per well 24 h before the imaging. Then the cells were transfected with Bac-Mam baculoviruses of Sig1R-YFP (MOI = 3) and 2 h before the imaging the culture medium was exchanged by photostable cell culture medium LiveLight™ MEMO. The imaging experiments were performed at 37°C in 5% CO2 atmosphere. After selection of ROI and adjustment of HILO illumination angle the videos were acquired using continuous illumination with 515 nm laser and 10 ms exposure time per frame. SRRF images were reconstructed using NanoJ-SRRF plugin (100 frames per time point [62], magnification: 5, temporal analysis settings: TRPPM). Bright fluorescent spots were automatically extracted using wavelet spot detector in Icy software [63] and tracked with spot tracking block which relies on Multiple Hypothesis Tracking algorithm [64] (motion mode: directed, optimization: LPsolver, filter out trajectories < 5 frames duration).

    (MP4)

    Attachment

    Submitted filename: Response_to_reviewers_REV1.docx

    Data Availability Statement

    All relevant data are within the manuscript and its Supporting Information files.


    Articles from PLoS ONE are provided here courtesy of PLOS

    RESOURCES